WHO Pharmaceuticals Newsletter No. 2, 2016

OMS, 19 de abril de 2016

Contenido

Asuntos Regulatorios

Carbamazepine .................................................................................. 5

Cisplatin ............................................................................................ 5

Entecavir hydrate .............................................................................. 5

Eribulin mesylate ............................................................................... 6

Esomeprazole magnesium hydrate .................................................... 6

Flunitrazepam .................................................................................... 6

Furosemide......................................................................................... 7

Fusafungine nose and mouth sprays .................................................. 7

Idelalisib ........................................................................................... .7

Imatinib mesylate .............................................................................. .8

Inhaled corticosteroids for chronic obstructive pulmonary disease ... 8

Loxoprofen ........................................................................................ .8

Methylphenidate hydrochloride ...........................................................9

Mirabegron ...........................................................................................9

Mycophenolate mofetil ........................................................................9

Opioid pain medicines ........................................................................ 10

Natalizumab .................................................................................... ..10

Piperacillin and tazobactam combination ............................................11

Piperacillin containing products (alone or in combination with tazobactam)  11

Risperidone and paliperidone ............................................................. 12

Simeprevir........................................................................................... 12

Sodium-glucose co-transporter-2 (SGLT2) inhibitors ....................... 12

Verteporfin ......................................................................................... 13

Seguridad de medicamentos

Bcr-Abl tyrosine kinase inhibitors........................................................ 14

Levonorgestrel-releasing intrauterine systems .................................. 14

Nicorandil ............................................................................................ 14

Pseudoephedrine containing over-the-counter products .................... 15

Rivaroxaban ......................................................................................... 15

Spironolactone and renin-angiotensin system drugs ........................... 15

Ticagrelor ............................................................................................ 16

Trametinib .............................................................................................16

Valproate ............................................................................................. 17

Vit.D3® (colecalciferol) ........................................................................17

Señales

Levetiracetam and impaired renal function .......................................... .18

Benznidazole and severe skin reactions ................................................24

Feature

Seasonal Malaria Chemoprevention and Pharmacovigilance,

Rabat, Morocco, February 2016 ..........................................................26

disponible en línea en http://bit.ly/1U8AZ2V